| INTRODUCTION
The prothrombin time (PT) is widely used for monitoring vitamin K antagonist anticoagulant therapy. It is also used as a screening test for single or combined deficiencies of the extrinsic coagulation pathway due to inherited defects or acquired defects due to liver disease. 1 Currently, there is considerable interest in the sensitivity of PT reagents to direct oral anticoagulants (DOACs) because DOAC might interfere in screening for coagulopathies in patients bleeding where the anticoagulation status of the patient is unknown, and in determining whether a patient is still anticoagulated (eg, prior to surgery). 2, 3 Recombinant thromboplastins using recombinant tissue factor (generated in bacteria) and synthetic phospholipids are sensitive PT reagents which overcome much of the lot-to-lot availability associated with thromboplastins prepared from traditional biological sources. 4, 5 Insect systems are widely used to produce proteins from higher eukaryotes because they have a similar pattern of glycosylation, phosphorylation and protein processing. We report on the performance of a novel prothrombin time reagent (Revohem™ PT, Sysmex
Corporation, Kobe, Japan) which utilizes human recombinant tissue factor produced by the silkworm-baculovirus expression system 6 and synthetic phospholipids. Revohem™ PT was tested for imprecision, stability and comparability to two widely used PT reagents (Reagent A and Reagent B) in a wide range of sample types. 
| MATERIALS AND METHODS

| RESULTS
Locally assigned ISI values were 1.00 for Revohem™ PT, 1.02 for Reagent A and 1.07 for Reagent B. Revohem™ PT demonstrated <1% imprecision with both normal and abnormal control plasmas over 5 days (Table 1) . To assess reagent stability, freshly reconstituted normal and abnormal controls were tested at day 0, day 4, day 7 and day
8 using an open 8-mL vial of Revohem™ PT which was stored onboard the analyser. After 7 days, the PT measurements for the normal and abnormal control plasmas had decreased by 4.1% and 5.4% relative to day 0. Normal reference ranges and geometric mean PTs were established in 140 normal plasmas (Table 2 ).
Comparability was assessed in 100 plasma samples from pa- The effect of haemostatic abnormalities secondary to liver disease was studied in 45 patients with a median MELD score 9 of 15 (range 9-32).
Good correlation was observed between reagents ( Figures 3D-F) . A small but statistically significant difference between Revohem™ PT and Reagent A (Wilcoxon signed rank P=.008) was observed, but this difference was not clinically significant (all <0.5 PT ratio).
The sensitivity for specific factor deficiencies was determined by plotting the factor level against PT ( Figures 3A-D) to determine the highest concentration of a given factor to produce prolongation of the 
| DISCUSSION
We report on the performance of the first PT reagent to use human recombinant tissue factor generated by the silkworm-baculovirus expression system. The comparison reagents were less sensitive to reduction in FII than to reductions in FV, FVII and FX as previously reported. 4 The sensitivity of Revohem™ PT to FV, FVII and FX was similar to that of the comparison reagents. Reagent B was slightly more sensitive to FII than Revohem™ PT or Reagent A. The prothrombin time is known to have limited utility for the detection in mild clotting factor deficiencies in the extrinsic pathway. 13 It should be emphasized that the prothrombin time is a global test, which is influenced by the levels of all clotting factors within a spiked deficient plasma, not just the clotting factor that has been adjusted. 14 Although guidance is available on the assessment of coagulation factor sensitivity of the APTT, 15 no clear information has been provided for PT, but it is generally assumed that similar mixing studies may be informative. The factor sensitivity data and ISI determination both indicate that Revohem PT is highly sensitive to factors II, V, VII and X. 16 The apparent oversensitivity to factors V, VII and X may be explained by the inherent problems with error associated with mixing tests, including problems with mixing plasmas from different sources, the impact of any buffers and stabilizers that a manufacturer may have added (in both PT reagents and plasmas), as well as differences in citrate concentration. In the case of factor V, due to its thermal lability, it is also possible that there is some loss of FV activity during the course of the experiment, so that actual FV levels were lower than those predicted. Figure 3 ) support this. Unfortunately, it was not possible to obtain sufficient samples from patients receiving dabigatran or apixaban to compare with drug-spiked plasmas. Although the PT should not be used to determine the plasma concentration of DOACs, it is important that laboratories know the sensitivity of its PT reagent to them.
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In conclusion, Revohem™ PT showed comparable or improved performance relative to two widely used PT reagents and is suitable for use in the control of warfarin, detection of inherited factor II, V, VII and X deficiency and assessment of coagulopathy in liver disease.
